Sign In

Submission Deadlines

Abstract submissions are now being accepted. Submit your work for consideration.

  • Opens: Wednesday, February 28, 2018 at 9:00 am ET
  • Closes: Wednesday, May 2, 2018 at 11:59 pm ET


Abstracts submitted will be reviewed by the Program Chairs for potential poster presentation. If selected, the presenting author will be required to accept the invitation to present, register for the conference, and provide current financial disclosure information.

Abstract notification will be sent to presenting authors in mid-May.


For questions about the abstract submission process, send an email to

Abstract Submission Guidelines


The title should be brief, but long enough to identify the nature of the study. Omit author names and medical degrees and institutional appointments in the title. The maximum for the title character count is 300.

Abstract Body

The body of the abstract needs to include:

  • A background
  • Description of methods
  • Summary of results obtained
  • Statement of conclusion reached

There is a set 3,000 maximum character count for the abstract body.


You may include any supporting images/tables. Images and tables are not a part of the overall character count.
Accepted files: pdf, jpg, jpeg, png, csv, doc(x), and ppt under 5MB

Author Types

Only one presenting and corresponding author may be selected – see author definitions below

  • Co-Author – One of several authors who provided a significant contribution to the abstract.
  • Corresponding Author – This author will receive all notifications regarding the abstract, and will be expected to make any changes requested by the abstract reviewers.
  • Presenting Author – The author who will be presenting the poster at the meeting.

The maximum number of authors on an abstract is 30.

Abstract Policies

Ethics Policy

The initial responsibility for adherence to ethical guidelines lies with the responsible investigators submitting their research findings to AASLD meetings or journals. First, for reports of research using human subjects, provide assurance that (a) informed consent in writing was obtained from each patient and (b) the study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a prior approval by the appropriate institutional review committee. Refer to individual patients by number, not by initials. HEPATOLOGY will only accept papers for review from liver transplant centers that explicitly state that no donor organs were obtained from executed prisoners or other institutionalized persons. Papers without such explicit statements will be returned without review.

Second, in studies involving animal experimentation, provide assurance that all animals received humane care according to the criteria outlined in the Guide for the Care and Use of Laboratory Animals [PDF] prepared by the National Academy of Sciences and published by the National Institutes of Health (NIH publication 86-23 revised 1985).

Disclosure Policy

It is the policy of the American Association for the Study of Liver Diseases (AASLD) to ensure balance, independence, objectivity, and scientific rigor in all its individually or jointly provided educational programs. All faculty/authors participating in any AASLD sponsored programs, as well as planners and committee members are expected to disclose any real or apparent conflict(s) of interest that may have a direct bearing on the subject matter of the continuing medical education program.

All abstract authors must complete their own financial disclosure statement either disclosing all financial relationships with commercial interests or indicating that none exist. Submitting authors will NOT be allowed to submit disclosures on a co-author's behalf.